nothing in Duchenne cardiomyopathy has come close to 4 years of ejection fraction stability in non-ambulant patients. This level of sustained cardiac preservation is unprecedented and not commonly discussed because it hasn’t existed—until now. $CAPR #DMD#Deramiocel#RareDisease
Capricor’s quarterly conference call and webcast is starting at 4:30 p.m. ET today. <<<Click the link to access the webcast https://t.co/ddU5SDEbSx>>>
$CAPR #RareDisease
This weekend at the American Heart Association Scientific Sessions 2026, Dr. Jonathan Soslow of Vanderbilt received the Outstanding Research Award in Pediatric Cardiology for his presentation of the HOPE-3 cardiac results for Deramiocel in Duchenne muscular dystrophy. Congratulations, Dr. Soslow, and thank you to the patients, families and investigators who made this research possible.
Read the press release: https://t.co/ImKWORpWQW
#AHA26 #Duchenne #DMD #ScientificSessions26 #Deramiocel $CAPR
Dr. Craig McDonald and the other 28 physician-scientists/investigators in HOPE-3 have spoken! @FDA trust the expert DMD physicians who work with us patients the most.
Approve Deramiocel! $CAPR
Read the full letter on Dr. McDonald’s LinkedIn by clicking this link: https://t.co/gFQnFgavSy
September 7th is World Duchenne Awareness Day! On this day, the global Duchenne community comes together to raise our voices for #Duchenne and #Becker. This year we recognize the importance of access for our community. Share your story this September 7th on #WDAD2026.
Today, we join the global community in recognizing World Duchenne Awareness Day. This year’s theme, “Access Changes Lives,” reminds us that meaningful progress goes beyond just scientific breakthroughs. It means ensuring that individuals living with Duchenne and Becker muscular dystrophy have access to the care, support, and opportunities they need. At Capricor, we remain committed to continuing to push forward with Deramiocel and our mission to help make a difference in the lives of those living with DMD. Together, we can raise awareness, inspire action, and work toward a brighter future for the Duchenne community. 💚
$CAPR #WDAD2026 #DuchenneAwareness #DMD #AccessChangesLives #Deramiocel
“The most important takeaway from our decade of clinical work in Duchenne muscular dystrophy is that every study points in the same positive direction across both skeletal and cardiac function.
Lightning does not typically strike three times in the same place.” #DMD#deramiocel
In a matter of weeks, years of science and patient hope will finally meet their opportunity🙏🏻 #Deramiocel#DMD $CAPR Too many focus on noise and controversy and forget the boys and families this could help. Time is muscle
Happy Mother’s Day 💙
The love, strength, and fierce dedication of Duchenne moms and mom figures is unmatched—and today, we’re celebrating all of you.
Thank you for being the heart of this community and for everything you do, seen and unseen.
#MothersDay#Mom
HOPE-3 is the first Phase 3 randomized controlled trial in advanced Duchenne muscular dystrophy to hit every pre-specified primary and secondary endpoint. No therapy in the history of this disease has done that in this patient population.
At the American Academy of Neurology (AAN) 2026 Annual Meeting in Chicago, Capricor will be presenting Phase 3 HOPE-3 results for Deramiocel in a late-breaking oral presentation later today. The presentation highlights previously reported topline data demonstrating significant functional benefits in patients with Duchenne muscular dystrophy (DMD). For more information, please click https://t.co/icJhFL0gA3
$CAPR #Deramiocel #DMD #AANAM #Duchenne
@US_FDA @DrMakaryFDA No excuses to keep boys with Duchenne waiting for a now proven therapy. With all the public talk about speed and flexibility, you owe it to a community that has neither. Capricor has met the standard every step of the way. The time is now
It has already earned Orphan Drug, RMAT, Rare Pediatric Disease, and ATMP designations across the US and EU, all recognizing serious unmet need and promising evidence. Families are still waiting for access to the very therapy those designations were meant to speed.
$CAPR